Ajinomoto

CONSUMERS GLOBALLY DEFLECT RESPONSIBILITY OF SODIUM INTAKE

Retrieved on: 
Thursday, March 3, 2022
SALTS, United Kingdom, Longevity, Research, Organic acid, View, Income, Public health, Doctor of Philosophy, Eating, Sodium, Ajinomoto, Solution, Nutrient, Multimedia, Sale, Food, Fruit, Taste, Vegetable, Health, Lithium, Dietary supplement, Salt, Food preservation

The conundrum reveals itself. Consumers indicate that they would prefer their grocery store not sell high-sodium foods. In theory, this makes sense--If something is not available, behavior change is inevitable. However, in reality, consumers would not be happy if high-sodium foods were removed from store shelves. The survey indicated that the majority of consumers prioritize taste above all else when deciding what to eat and currently believe low-sodium foods are bland and tasteless.

Key Points: 
  • The SALTS Survey was conducted across seven global markets in North America, Europe and Asia-Pacific to understand consumers' attitudes towards sodium and identify opportunities to develop partnerships and tools to reduce sodium consumption overall.
  • The survey found the large majority of consumersrecognize various health benefits associated with reducing their sodium intake from health maintenance to illness prevention to increased longevity.
  • Sixty-four percent of consumers know that eating too much sodium is bad for their health, yet only thirty-seven percent pay attention to how much sodium they consume.
  • Sodium ranked six out of ten globally in consumers' food and nutrition priorities.

Global Functional Food Ingredients Market Report 2021: COVID-19 Impacts, Growth and Changes to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 9, 2021
Food, Beverage, Retail, Flower, Yeast, Carotenoid, Mineral, Cancer, Tate, ADM (company), Food science, DSM, Health, Kerry Group, Degenerative disease, Income, Growth, Nutrient, COVID-19, Ajinomoto, Human, Vitamin, Ingredion, Arla Foods, Drink, BASF, Dairy, Cargill, Probiotic, Tate & Lyle, Roquette Frères, Fortification, Plant, Nutritional science, Dietary supplement, Bottled water

The "Functional Food Ingredients Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Functional Food Ingredients Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major companies operating in the functional food ingredients sector are focused on partnering or collaborating with other companies to develop innovative solutions for functional food ingredients.
  • The rise in demand for fortified food & beverage products is expected to contribute to the growth of the functional food ingredients market.
  • Therefore, the rise in demand for fortified food & beverage products will drive the functional food ingredients market growth.

Global L-Carnitine Market Report 2021: Size, Share & Trends Analysis by Process (Bioprocess, Chemical Synthesis), Product (Food & Pharmaceutical Grade, Feed Grade) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Pharmaceutical, Health, Fitness & Nutrition, Cayman Chemical Company, CGMP, Awareness, CAGR, Ajinomoto, Growth, ISO, Merck Group, Infertility, Weight, USD, Enzyme, Male, Process, Contract, Food, SSOP, Application, Bioprocess, Research, Degenerative disease, Fine chemical, Agriculture

The "L-Carnitine Market Size, Share & Trends Analysis Report by Process (Bioprocess, Chemical Synthesis), by Product (Food & Pharmaceutical Grade, Feed Grade), by Application, by Region, and Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "L-Carnitine Market Size, Share & Trends Analysis Report by Process (Bioprocess, Chemical Synthesis), by Product (Food & Pharmaceutical Grade, Feed Grade), by Application, by Region, and Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global L-carnitine market size is expected to reach USD 276.0 million by 2028, expanding at a CAGR of 5.1%.
  • Growing consumer awareness regarding product benefits, along with increasing demand from end-use industries such as pharmaceutical, nutraceutical, and animal feed, is projected to drive the market over the forecast period.
  • L-carnitine and its derivatives are used for numerous applications including male infertility, kidney treatment, cardiovascular diseases, weight reduction, and bone mass.

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

Retrieved on: 
Monday, September 27, 2021
Multifocal choroiditis and panuveitis, UC, Colectomy, Psoriasis, Hematochezia, Crohn's disease, Bechet, Ajinomoto, Adalimumab, Degenerative disease, Abdominal pain, Virology, Gastroenterology, LinkedIn, Adult, Disease, Immune system, Anemia, Twitter, Co-promotion, Ulcerative colitis, Maintenance, Fever, Inflammatory bowel disease, Erosion, Gastrointestinal disease, Patient, Uveitis, Pediatrics, Inflammation, YouTube, Marketing, Eisai, Neurology, Economic cost, Neuroscience, Rheumatoid arthritis, ACCA, Ankylosing spondylitis, Instagram, Diagnosis, Hidradenitis suppurativa, Juvenile idiopathic arthritis, Psoriatic arthritis, Bacteria, Prevalence, Pyoderma, AbbVie, Structural Damage, Pustular psoriasis, Pharmaceutical industry, Medicine, Health insurance, Vaccine, Aluminium, Fine chemical, Dietary supplement

TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").

Key Points: 
  • TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").
  • It remains a long-term condition that is not adequately controlled in some patients; more treatment options are needed.
  • The disease rarely develops in childhood, with an estimated prevalence in Japan of 15 per 100,000 between the ages of 0 to 19.
  • HUMIRA is a fully human anti-TNF-alpha monoclonal antibody.

Antibody-Drug Conjugate Therapeutic Window Enhancement, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 15, 2021
Lysine, CMDO, Technology, Antibody, Control, Ajinomoto, Therapeutic index, Industry, Cleavage, Toxicity, Food, ADC, Immunoglobulin G, Cysteine, Fine chemical

The heterogeneous nature of these stochastic ADCs can cause diminished efficacy and increased toxicity, thus limiting the corresponding therapeutic index.

Key Points: 
  • The heterogeneous nature of these stochastic ADCs can cause diminished efficacy and increased toxicity, thus limiting the corresponding therapeutic index.
  • Overall, Aji Bio-Pharma's site-specific conjugation technology coupled with a novel cleavable linker, reduces heterogeneity, thus simplifying manufacturing and characterization of the ADCs, and enhances biological properties by increasing the therapeutic window.
  • For more information, or to register for this event, visit Antibody-Drug Conjugate Therapeutic Window Enhancement.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"

Retrieved on: 
Monday, September 13, 2021

"Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location.

Key Points: 
  • "Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location.
  • This service is intended to allow patients to shorten the time required to receive support tools and reduce the burden of carrying them.
  • Through providing "Humira Support Tool Ordering Service for Patients," AbbVie, Eisai, and EA Pharma are committed to further enhancing patient support programs and contributing to improved treatment adherence.
  • EA Pharma Co., Ltd., is a gastrointestinal specialty pharmaceutical company with a full value chain covering R&D, production & logistics and sales & marketing.

Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite

Retrieved on: 
Tuesday, May 25, 2021
Ajinomoto, Syringe, Flexibility, Companies, Science and technology, Technology

Along with the line, the fill suite houses two formulation suites, one of which is capable of handling flammable (class H) compounds.

Key Points: 
  • Along with the line, the fill suite houses two formulation suites, one of which is capable of handling flammable (class H) compounds.
  • The high-speed process is rated to move 22,000 syringes per hour through the line, with a batch capacity of over 200 thousand syringes.
  • "This expansion provides a significant increase in our current aseptic fill/finish capacity and allows for additional scheduling flexibility, as well as component flexibility," says Paul Ruther, Director, Drug Product Manufacturing, Ajinomoto Bio-Pharma Services.
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.

Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite

Retrieved on: 
Tuesday, May 25, 2021
Ajinomoto, Syringe, Flexibility, Companies, Science and technology, Technology

Along with the line, the fill suite houses two formulation suites, one of which is capable of handling flammable (class H) compounds.

Key Points: 
  • Along with the line, the fill suite houses two formulation suites, one of which is capable of handling flammable (class H) compounds.
  • The high-speed process is rated to move 22,000 syringes per hour through the line, with a batch capacity of over 200 thousand syringes.
  • "This expansion provides a significant increase in our current aseptic fill/finish capacity and allows for additional scheduling flexibility, as well as component flexibility," says Paul Ruther, Director, Drug Product Manufacturing, Ajinomoto Bio-Pharma Services.
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.

Ajinomoto Health & Nutrition North America, Inc. Opens New Corporate Headquarters with State-of-the-Art Culinary Kitchen

Retrieved on: 
Thursday, April 29, 2021
Ajinomoto, Food science, Nutrition, Articles, Nutraceutical, Companies, Health

b'ITASCA, Ill., April 29, 2021 /PRNewswire/ --Ajinomoto Health & NutritionNorth America, Inc., announces the opening of itsnew NorthAmericancorporateheadquartersat250 East Devon Avenue in Itasca, Illinois.

Key Points: 
  • b'ITASCA, Ill., April 29, 2021 /PRNewswire/ --Ajinomoto Health & NutritionNorth America, Inc., announces the opening of itsnew NorthAmericancorporateheadquartersat250 East Devon Avenue in Itasca, Illinois.
  • That flexibility is a gamechanger for us," says Chef ChrisKoetke, Corporate Executive Chef atAjinomoto Health & Nutrition.\nAbout Ajinomoto Health & Nutrition North America, Inc.\nAjinomoto Health & Nutrition North America, Inc. is awholly-ownedsubsidiary of Ajinomoto Co., Inc., a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries, as well as food ingredients.
  • Ajinomoto Health & Nutrition North America, Inc. leverages an international manufacturing,supplyand distribution chain to bring the highest-grade products to customers.
  • For additional information on Ajinomoto Health & Nutrition North America, Inc., pleasevisit http://www.ajihealthandnutrition.com .\n'

Pegasus Tech Ventures Announces Collaboration Plan with Japan’s Food Giant Ajinomoto Co., Inc. on Global Startup Deal Sourcing

Retrieved on: 
Monday, March 29, 2021
Research, Fitness & Nutrition, Food, Beverage, Health, Retail, Agriculture, Other Science, Science, Natural Resources, Finance, Geography of California, Money, Entrepreneurship, Santa Clara County, California, Silicon Valley, Ajinomoto, Venture capital

Pegasus Tech Ventures (Pegasus), a Silicon Valley-based global venture capital firm which supports innovation for global corporations, announced a business collaboration with Japans food giant Ajinomoto Co., Inc. (Ajinomoto Co).

Key Points: 
  • Pegasus Tech Ventures (Pegasus), a Silicon Valley-based global venture capital firm which supports innovation for global corporations, announced a business collaboration with Japans food giant Ajinomoto Co., Inc. (Ajinomoto Co).
  • Ajinomoto Co. plans to expedite its global expansion through Pegasus, which has presence in 16 locations around the world, including their headquarters in Silicon Valley.
  • "We are a global venture capital firm and see many food tech and healthcare related startups around the world, said Anis Uzzaman, Founder & CEO of Pegasus Tech Ventures.
  • Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management.